Payment overview · 2025
General Payments
$209.35
10 reported records · 4 companies
Healthcare provider profile · identity verified
Patrick Sellers, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BOAZ, AL · NPI 1205342268
Verified facts
What the public records show
CMS Open Payments records show Patrick Sellers, CRNP received $209.35 in general payments during 2025 across 10 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.38 | 42.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.66 | 31.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.57 | 18.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.74 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.35 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $89.38 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.66 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 223 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 60 |
| Omeprazole | Omeprazole | 162 | 53 |
| Fenofibrate | Fenofibrate | 150 | 42 |
| Losartan Potassium | Losartan Potassium | 130 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 121 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 46 |
| Metformin Hcl | Metformin Hcl | 114 | 48 |
| Trazodone Hcl | Trazodone Hcl | 103 | 41 |
| Buspirone Hcl | Buspirone Hcl | 98 | 27 |
| Carvedilol | Carvedilol | 97 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 84 | 29 |
| Furosemide | Furosemide | 84 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 30 |
| Meloxicam | Meloxicam | 75 | 20 |
| Montelukast Sodium | Montelukast Sodium | 74 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 18 |
| Farxiga | Dapagliflozin Propanediol | 61 | 21 |
| Methocarbamol | Methocarbamol | 61 | 13 |
| Ozempic | Semaglutide | 61 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 12 |
| Simvastatin | Simvastatin | 49 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 20 |
| Cefdinir | Cefdinir | 46 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 17 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 18 |
| Potassium Chloride | Potassium Chloride | 41 | 17 |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Gabapentin | Gabapentin | 37 | 18 |
| Celecoxib | Celecoxib | 34 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Mounjaro | Tirzepatide | 34 | 14 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 12 |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Eliquis | Apixaban | 27 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Constulose | Lactulose | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 12 |
| Nifedipine Er | Nifedipine | 25 | 13 |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Prednisone | Prednisone | 19 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Primidone | Primidone | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.35 · 10 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, COMIRNATY, ELIQUIS, Kerendia, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error